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This study was designed to clarify the cardioprotective
effects of various class I antiarrhythmic drugs, i .e., aprin-
dine, disopyramide, flecainide, lidocaine, mexiletine, pen-
tisomide and propafenone, on the ischemic heart . Sixty-one
adult mongrel dogs were classified into eight groups accord-
ing to premedication   1) control group, physiologic saline
solution was administered intravenously 25 min before left
anterior descending coronary artery ligation ; 2) aprindine
group, 3 mg/kg body weight of aprindine intravenously ; 3)
disopyramide group, 2 mg/kg of disopyramide intrave-
nously ; 4) fiecainide group, 2 mg/kg of flecainide intrave-
nously followed by drip infusion of 100 µg/kg per min ; 5)
lidocaine group, 2 mg/kg of lidocaine intravenously fol-
lowed by drip infusion of 100 µg/kg per min ; 6) mexiletine
group, 3 mg/kg per min of mexiletine intravenously fol-
lowed by drip infusion of 15 µg/kg per min ; 7) pentisomide
group, 5 mg/kg intravenously ; and 8) propafenone group, 2
mg/kg intravenously. Arterial blood pressure and electro-
cardiogram were monitored throughout the experiment .
Two hours after coronary occlusion, the heart was
excised. Myocardial mitochondria were prepared and mito-
Ventricular arrhythmias in patients with acute myocardial
infarction are significant clinical challenges . Immediate rec-
ognition of rhythm disturbances, appropriate assessment of
precipitating factors and prompt initiation of appropriate
therapy are crucial in the management of arrhythmias .
Advances in electrophysiology contribute significantly to
clarifying the genesis and management of arrhythmias . Sev-
eral biochemical derangements have been implicated in the
genesis of arrhythmias related to acute ischemia (1) . Accord-
ingly, it is deduced that lessening of the severity of ischemia
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chondrial function (the respiratory control index and the
rate of oxygen consumption in state III) was measured
polarographically . Fractionation of myocardial tissues was
performed and the lysosomal enzyme (N-acetyl-/3-glucos-
aminidase and J3-glucuronidase) activities among fractions
were measured .
No significant hemodynamic changes were observed
compared with the control group except for those in the
disopyramide and flecainide groups; that is, decrease in
heart rate without changes in blood pressure compared
with the control group was observed .
All antiarrhythmic drugs effectively prevented the de-
velopment of ventricular arrhythmias associated with isch-
emia. Two hours of coronary occlusion induced mitochon-
drial dysfunction and leakage of lysosomal enzymes . In
contrast, each antiarrhythmic drug without exception less-
ened mitochondrial dysfunction and prevented the leakage
of lysosomal enzymes concomitantly . These results indicate
that class I antiarrhythmic drugs have cardioprotective
effects on ischemic myocardium .
(J Am Coll Cardiol 1 8 ;14 21 -24)
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is closely related to improvement of predisposing conditions
for lethal arrhythmias . Beta-adrenergic blockers, class 11 and
calcium channel antagonists, class IV antiarrhythmic drugs
have cardioprotective effects on the ischemic heart (2-5) .
Furthermore, recent studies (6) revealed that amiodarone, a
class III antiarrhythmic drug, protects myocardial mitochon-
dria against ischemia . In addition, it is reported (7,8) that
cardioprotective drugs, which are not classified as class I to
IV antiarrhythmic drugs, showed an antiarrhythmic effect on
the ischemic heart . Therefore, the relation between antiar-
rhythmic effect and cardioprotective effect has attracted
much interest . Nevertheless, little information is available
concerning the biochemical effects of class I antiarrhythmic
drugs, the most widely used antiarrhythmic agents, on the
ischemic heart ( ) .
In this study, we estimated the cardioprotective effects of
various class I antiarrhythmic drugs on the ischemic heart by
0715-10 7/8 /$3 .50
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measuring changes in mitochondrial function and leakage of
lysosomal enzymes as biochemical markers in the ischemic
heart .
Methods
Animal preparation . Sixty-one adult mongrel dogs of
either gender, weighing 7 to 12 kg, were anesthetized with
sodium pentobarbital (50 mg/kg body weight) intraperitone-
ally . The dogs were intubated and ventilated with a Harvard
type respirator (Igarashi Ika Kogyo). Lead II of the electro-
cardiogram (ECG) was monitored continuously throughout
the experiment by a VC-640G oscillographic recorder
(Nihon Kohden) and recorded simultaneously by an ICR-
7200 ambulatory ECG recorder (Nihon Kohden) . Catheters
were placed in the right femoral artery and vein for moni-
toring aortic blood pressure (AD-600, Nihon Kohden) and
for administration of drugs and adequate hydration, respec-
tively . A left thoracotomy was performed in the fourth or
fifth intercostal space, and the heart was suspended in a
pericardial cradle . The left anterior descending coronary
artery immediately distal to the first diagonal branch was
dissected free and a silk suture was placed around the
coronary artery for acute occlusion . Two hour occlusion was
performed by ligating the vessel . The experiments per-
formed conform to the Position of the American Heart
Association on Research Animal Use adopted November 11,
1 84 by American Heart Association .
Experimental design . The 61 dogs were classified into
eight groups . In the control group (n = 12) . physiologic
saline solution was administered intravenously throughout
the experiment. In the aprindine group (n = 7), 25 min before
coronary occlusion, 3 mg/kg of aprindine hydrochloride
dissolved in 25 ml of saline solution was administered
intravenously for 10 min. In the disopyramide group (n = 7),
25 min before coronary occlusion, 2 mg/kg of disopyramide
hydrochloride dissolved in 25 ml of saline solution was
administered intravenously for 10 min. In the flecainide
group (n = 7), 25 min before coronary occlusion, 2 mg/kg of
flecainide acetate dissolved in 5 ml of distilled water was
administered intravenously for 10 min followed by a con-
stant infusion of 100 µg/kg per min dissolved in water (20 ml)
with use of an infusion pump . In the lidocaine group (n = 7),
25 min before occlusion, 2 mg/kg of lidocaine hydrochloride
dissolved in 5 ml of saline solution was administered intra-
venously for 10 min followed by a constant infusion of 100
µg/kg per min dissolved in saline solution (20 ml) with use of
an infusion pump . In the mexiletine group (n = 7), 3 mg/kg of
mexiletine hydrochloride dissolved in 5 ml of saline solution
was administered intravenously for 10 min followed by a
constant infusion of 15 µg/kg per min dissolved in saline
solution (20 ml) with use of an infusion pump . In the
pentisomide group (n = 7), 25 min before coronary occlu-
sion, 5 mg/kg of pentisomide dissolved in 25 ml of water was
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administered intravenously for 10 min . In the propafenone
group (n = 7), 25 min before coronary occlusion, 2 mg/kg of
propafenone dissolved in 25 ml of water was administered
intravenously for 10 min .
Hemodynamic measurements . Arterial blood pressure and
heart rate were monitored throughout the experiment as
described in the animal preparation section. To compare heart
rate easily, delta heart rate was used ; this was defined as the
difference between heart rate at preinjection (physiologic
saline solution or drugs) and that during the period observed .
Analysis of arrhythmias . With the ambulatory ECG mon-
itor, the number of premature ventricular beats during a 2 h
period of occlusion was recorded and analyzed by an auto-
analyzer (DMC-3110, Nihon Kohden). To express the sever-
ity of arrhythmias, the total number of ventricular premature
beats, the arrhythmia ratio (defined as the number of ven-
tricular premature beats divided by the total heartbeats) and
the total duration time of ventricular tachycardia were used .
Ventricular tachycardia was defined as more than three
successive ventricular premature beats .
Measurement of mitochondrial function . Two hours after
occlusion of the left anterior descending coronary artery, to
distinguish the ischemic area from the nonischemic area,
Evans blue dye was infused through the femoral vein . Heart
mitochondria from the nonischemic area and the ischemic
area in each group were prepared by differential centrifuga-
tion according to the method of Hatefi et al . (10) . The rate of
oxygen consumption in state III and the respiratory control
index were measured . Oxygen consumption in mitochondria
was measured polarographically with an oxygen electrode
(UC-12, Central Kagaku) and a closed cell as described
previously (11) . The incubation medium contained 0 .3 M
mannitol, 10 mM potassium chloride, 10 mM potassium
phosphate, 2 .5 mM magnesium chloride and 0 .25 mM ethyl-
enediaminetetraacetic acid, pH 7 .4, in a total of 0.7 ml .
Respiration was initiated by addition of 0 .03 ml of mitochon-
dria) suspension (10 mg protein/ml), and then 0 .2 M succinic
acid (0.03 ml) as substrate and 10 mM adenosine diphosphate
(0.03 ml) were subsequently added. The rate of oxygen
consumption in state III was calculated from mitochondrial
oxygen consumption in number of atoms of oxygen con-
sumed per milligram of mitochondrial protein per minute
during state III respiration. The respiratory control index
was taken as the ratio between the rate of oxygen consump-
tion before and after the addition of adenosine diphosphate .
Measurement of lysosomal enzyme activities . According
to the methods of Ruth et al . (12) and Kennett and Weglicki
(13), the endocardial tissue from the nonischemic area and
the ischemic area in each group was immersed in the
extraction medium (0 .25 M sucrose, 0 .6 M potassium chlo-
ride, I mM adenosine triphosphate, i mM ethylenediamine-
tetraacetic acid and 1 mM magnesium chloride, buffered
with imidazole at pH 7.2) . The tissue was then homogenized
with a Teflon pestle tissue grinder . Pellets were obtained by
JACC Vol . 14, No . I
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Table 1 . Hemodynamic Effects of Class I Antiarrhythmic Drugs
-30 min 0 min 30 min
differential centrifugation; the durations in minutes at the
various g forces were 1,000 g for 10 min, 2,500 g for 10 min,
 ,000 g for 10 min, 20,000 g for 30 min and 140,000 g for 60
min. They were resuspended in 0
.25 M sucrose containing 10
mM imidazole buffered at pH 7 .2. All pellets and the final
supernatant were assayed for total activity of N-acetyl-
/3-glucosaminidase and /3-glucuronidase with use of the
methods of Noto et al. (14) and Kato et al . (15) .
Materials . Aprindine hydrochloride, disopyramide hy-
drochloride, flecainide acetate, lidocaine hydrochloride,
mexiletine hydrochloride, penticainide and propafenone
were provided by Mitsui Pharmaceutical Co
., Ltd . ; Chugai
Pharmaceutical Co., Ltd . ; Eisai Co., Ltd . ; Fujisawa Phar-
maceutical Co., Ltd .
; Behlinger Pharmaceutical Co ., Ltd . ;
Meiji Seika Co ., Ltd . and Yamanouchi Pharmaceutical Co
.,
Ltd., respectively. Other chemicals were purchased from
Wako Co ., Ltd .
Statistics . The significance of all results was determined
with the Dunnett's test except for mortality, for which the
chi-square test was used
. Probability (p) values of <0 .05
were considered statistically significant
. All data in this
study were expressed as mean ± SD .
A
. Time Course of Systolic Blood Pressure (mm Hg) in All Groups
60 min  0 min 120 min
*p < 0 .01 versus the control group ; tp < 0 .05 . Values are mean ± SD   the time of coronary occlusion is expressed as 0 min .
Results
Of the 61 dogs that underwent coronary artery occlusion,
5 of the 12 dogs in the control group died of ventricular
fibrillation and were excluded from the subsequent analysis .
No dogs died in the drug-treated groups. Data for the
remaining 56 dogs form the basis of the report .
Hemodynamics (Table 1) . In the disopyramide and
flecainide groups, decreases in heart rate were observed
without significant changes in arterial blood pressure . How-
ever, neither arterial blood pressure nor delta heart rate in
the other drug-treated groups changed significantly from
values in the control group throughout the experiment .
Arrhythmias (Table 2)
. Administration of antiarrhythmic
drugs reduced significantly the total number of premature
ventricular beats compared with those of the control group
.
Similar tendencies were observed in the arrhythmia ratio and
the total duration of ventricular tachycardia .
Mitochondrial function (Table 3) .
In the control group,
the rate of oxygen consumption in state III in the ischemic
area was decreased significantly compared with that in the
nonischemic area . A similar tendency was observed in the
respiratory control index ; that is, a remarkable decrease in
Control
Aprindine
Disopyramide
Flecainide
Lidocaine
Mexiletine
Pentisomide
Propafenone
104 .3
114 .3
11 .3
110 .0
105 .7
116.4
111 .4
112 .1
± 8 . 
± 16 .2
± 21 .1
± 15 .0
± 10 .6
± 22 .3
± 31 .7
± 20 .2
106
.4
121 .4
104 .3
105 .0
104 .3
112 . 
107 . 
10  .3
1
6
. 
± 11 .1
± 13 .4
± 15 .3
± 8 . 
± 25 .5
1 28 .4
± 1  .7
107
. 
127 . 
106.4
110 .0
108 .6
112 .1
107 .1
105 .7
± 7 .0
± 7 .6
± 25 . 
± 20.4
± 12 .5
± 25 .3
± 21 .4
± 1 .0
110 .7 ± 13 .4
127. ±4 . 
10 .3±27 .8
106 .4 1 15 .2
111 .4 ± 12 .1
110 .0 ± 25 .4
107 .  ± 17 .5
102 .8 1 23 .2
106 .4 ± 15 .2
127 .1 ± 7 .6
107 .1 ± 30 . 
104
.3 ± 14 .6
107 .1 ± 13 .8
107 . 
3
23 .4
10  .3 ± 16 .2
100 .7 ± 27 .5
107 .1 ± 13 .2
127. ±5 .7
105.7±33 .3
103 .6 ± 17 .0
104 .3 ± 15 .4
105 .0 ± 20 .6
10  .3 ± 15
.7
103 .6 ± 28 .5
B . Time Course of Diastolic Blood Pressure (mm Hg) in All Groups
Control 72 .4 ± 11 .  73 .6 ±   .4 77 .  ± 8 .1 74
.3 1-
11 .0
73 .6 ± 7
.5
6  .3 ±   .3
Aprindine 80.7 ± 11 .0 82 .1
1
4 .  86 .4 ± 8 .0 86 .4 ±  .0 87 .1 ± 6 .4 87 .1 ± 7.0
Disopyramide 85 .0
± 13
.5
73
.6
± 14 .1 72
. 
± 14.7
77 .1 ± 15 .2 78.61-1  .5 74 .3 ± 17 . 
Flecainide 83 .6 ± 12 .5 7  .3 ± 12 .1 80.7 ± 12 .4 7  .3 ±   .3 76 .4 1 11 .1 77 .  ±   .1
Lidocaine 73 .6 ± 12 .5 72 .  ± 7 .6 72 .1 ± 6 .4 72 .  ± 7 .6 70 .7 1   .3 67 .  ± 10 .4
Mexiletine
85 .7
± 11 .0 80 .7 ± 15 .  78
.6
± 13 .5 77 .1 ± 13
.8
75
.7
1 15 .7 74 .3 ± 14 .0
Pentisomide 82 .  ± 26 .1 7  .3 ± 25 .1 80.0 ± 22 .5 7  .3 ± 1  .0 82.1±13 .8 81 .4 ± 12 .8
Propafenone 82 .  ± 15 .0
77
.1
± 14 .4 76
.4
± 15 .5 75
.7
± 15 .1 73
.6 ± 18 .2
75 .0 ± 17
.3
C . Time Course of Delta Heart Rate (beats/min) in All Groups
Control -6 .6 ±   .4 -10 .  ± 11 .8 -20 .0 ± 11 .1 -25 .  ± 12 .1 -2  .6 ± 13 .3
Aprindine -20.6 ± 10 .  -18 .  ± 14 .  -21 .4
1
15 .0 -24 .6 ± 16 .3 -28 .3 ± 14 .2
Disopyramide -32 .6
± 16.2* -43 .3 ± 21 .1* -47 .1 ± 23 .3t -50 .6 ± 26 .6 -54 .0 ± 25 .7
Flecainide -30.011  . t -34.3120 .71 -40 .3 ± 21 .0 -48 .0 21 .1 -58 .3 ± 28 .3
Lidocaine -8.3112 .7
-8.3115
.6
-12
.0115 .5
-1 
.7118 . 
-2 .7122
.6
Mexiletine -16 .0 1 14 .0 -22 .  1 5 .8 -2 .718 .8 -37.41  .1 -3 .117.6
Pentisomide -21.1118 .1 -25 .711  .2 -28.4120 .5 -30. 121 .  -33.7123 .2
Propafenone -23
.1118 .8 -26.6118
. 
-36. 122
.0
-44.6125 .7 -47.1127 .2
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Table 2. Total Number of Ventricular Premature Beats,
Arrhythmia Ratio and Total Duration of Ventricular Tachycardia
in All Groups
*p < 0 .01 versus the control group   tp < 0.05 . Values are mean ± SD .
the respiratory control index was observed in the ischemic
area. In all drug-treated groups, significant improvement of
the rate of oxygen consumption in state III in the ischemic
areas was observed compared with that of the control group,
although these values were lower than those from the
respective nonischemic areas . Similar results were observed
in the respiratory control index .
Lysosomal enzyme activities (Table 4) . In the ischemic
area, the activity of N-acetyl-/3-glucosaminidase was signif-
icantly decreased in the post  ,000 g to 140,000 g particulate
fractions ; conversely, the activity of N-acetyl-/3-glucosamin-
idase was increased significantly in the supernatant fraction
in the ischemic area . Similar tendencies were observed in the
activity of /3-glucuronidase in the control group . In all
antiarrhythmic drug-treated groups, decreases in the activity
of N-acetyl-/3-glucosaminidase in the  ,000 g, 20,000 g and
140,000 g fractions and increases in the activity of N-
acetyl-/3-glucosaminidase in the supernatant fraction in the
ischemic area were not observed. Similar tendencies were
observed in the activity of /3-glucuronidase ; that is, admin-
Table 3 . Indexes of Mitochondrial Function in All Drug Groups
istration of antiarrhythmic drugs prevented lysosomal en-
zyme leakage induced by 2 h coronary occlusion .
Discussion
Mitochondria and lysosomes  cardioprotective effects of
class I antiarrhythmic drugs . Myocardial ischemia produces
contractile, biochemical and structural abnormalities . Be-
cause ischemia causes a decrease in the supply of oxygen
and nutrition, there is a consequent marked decrease in
energy production in mitochondria with cessation of coro-
nary artery flow . Moreover, because mitochondria exclu-
sively produce high energy phosphate, particularly adeno-
sine triphosphate, maintenance of mitochondrial function is
of primary importance for maintaining cellular integrity .
Therefore, persistent mitochondrial dysfunction is suggested
to lead directly to cellular death (16) . Leakage of various
lysosomal hydrolytic enzymes might play an important role
in the irreversible changes in the ischemic myocardium (17) .
Hence, estimation of mitochondrial function and leakage of
lysosomal enzymes might be useful for assessing myocardial
injury after coronary occlusion .
In the present study, mitochondrial function in the ische-
mic area of the control group was decreased significantly
compared with that in the nonischemic area . Leakage of
lysosomal enzymes was also observed in ischemic myocar-
dium. Administration of each class I antiarrhythmic drug
lessened mitochondrial dysfunction induced by ischemia and
prevented leakage of lysosomal enzymes . The myocardial
injury associated with acute infarction is ascribed to both
ischemia itself and hemodynamic changes . The risk area
associated with left anterior descending artery occlusion was
estimated to be 30% to 40% (18,1 ) . Experimental ligation of
the left anterior descending coronary artery produces a
moderate-sized infarct without severe hemodynamic
changes, as observed in the present study . No drug signifi-
cantly changed either systolic or diastolic pressure . No
*n atoms/mg protein/min   '1p < 0.01 vs . nonischemic area
of the corresponding group   tp < 0 .01 versus ischemic
area of the control group . All values are mean
± SD.
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Respiratory Control Index
Rate of Oxygen Consumption in
State Ill*
Nonischemic
Area
Ischemic
Area
Nonischemic
Area
ischemic
Area
Control 4 .23 ± 0 .32 2.3 ±0
.36' 313 ± 31 161 ± 38t
Aprindine
4
.25
± 0 .22 3 .57 ± 0 .36'-1 320 ± 20 241 ± 32tt
Disopyramide 4 .24 ± 0.20 3 .36 ± 0 .27'-" 328 ± 27
267
± 24tt
Flecainide
4
.23
± 0.26 3 .2  ± 0.33t+ 326 ± 22 268 ± 20t$
Lidocaine 4 .18 ± 0 .16 3 .23 ± 0 .21-1-1 321 ± 26
26 
± 244
Mexiletine 4 .24 ± 0.27 3 .30 ± 0.37tt
318 ± 25 252 ± 38tt
Pentisomide 4 .24 ± 0 .26 3 .41 ± 0 .27'$ 312 ± 24 246 ± 37tt
Propafenone 4 .13 ± 0 .23 3 .43 ± 0 .38-1-+ 324 ± 22
260 ± 37tt
Total Number
of Ventricular
Premature
Beats
Arrhythmia
Ratio (%)
Total
Duration of
Ventricular
Tachycardia(s)
Control 416 .4 ± 275 .8 2 .57   1 .85 34 .5 ± 47 .8
Aprindine 16 .4 ± 24 .5* 0 .07 ± 0 .12* 0*
Disopyramide 4  .7 ± 53 .5* 0 .33 ± 0 .34* 1 .1 ± 2 .0*
Flecainide 38 .3 ± 3  .7* 0 .30 ± 0 .32* 1 .3 ± 3 .5*
Lidocaine 12 .1 ± 10 .4* 0 .06 ± 0 .07* 0 .1 ± 0 .2*
Mexiletine 6 .0 ± 11 .0* 0 .03 ± 0 .06* 0*
Pentisomide 87 .0 ± 41 .1 * 0 .5  ± 0 .31 * 2 .8 ± 2 .1 t
Propafenone 1  .4 ± 25 .2* 0 .1  ± 0 .20* 0*
JACC Vol . 14
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Table 4 . Lysosomal Activities in Control and Drug Treatment Groups
Fraction
1 .000 g 2,500 g  ,000 g
20,000 g 140,000 g Supernatant
A
. Total Activity of N-Acetyl-/3-Glucosaminidase (n mol/g wet weight per min) in Myocardial Fraction in the Control Group
*p < 0
.01 versus the control group or ischemic versus nonischemic area . t
p
< 0 .05 . All values are mean ± SD .
significant changes in delta heart rate except at 0, 30 and 60
min of coronary occlusion in the disopyramide group and at
0 and 30 min in the flecainide group were observed . In
addition, we estimated mitochondrial function and lysosom-
al enzyme activities in ischemic myocardium, which was
defined as the area not stained by Evans blue dye . Hence,
the beneficial effects of the class I antiarrhythmic drugs used
here might be based on the direct cardioprotective effects
and not on the improvement in hemodynamic status .
Efficacy of class I antiarrhythmic drugs in ventricular
arrhythmias . Ventricular arrhythmias associated with myo-
cardial ischemia may be a severe hazard that cardiologists
have to confront in the clinical setting, and many antiarrhyth-
mic agents have been developed . Vaughan Williams (20)
classified these antiarrhythmic agents into four categories
mainly on the basis of their electrophysiologic properties .
Class I type antiarrhythmic agents were classified into three
subgroups (21) based on their effect on action potential
duration. Disopyramide belongs to class la, aprindine,
lidocaine, mexiletine and pentisomide to class Ib, and
flecainide and propafenone to class Ic . Disopyramide is
reported to be effective for treatment of ventricular arrhyth-
mias in patients with suspected acute myocardial infarction
(22) . Aprindine is also effective in reducing ventricular ar-
rhythmias after acute infarction (23) . Lidocaine remains the
standard antiarrhythmic drug for ventricular arrhythmias dur-
ing the coronary care phase of acute myocardial infarction .
Koster and Dunning (24) reported that lidocaine, adminis-
tered by paramedics to patients with suspected myocardial
infarction, reduced the occurrence of ventricular fibrillation .
Mexiletine is a congener of lidocaine with similar chemical
and electrophysiologic properties . Clinical study confirmed
the efficacy of mexiletine for ventricular arrhythmias (25) .
Pentisomide is a well tolerated and effective compound of
potential value for treatment of ventricular arrhythmias (26) .
Flecainide is also a useful compound in patients with life-
threatening arrhythmias (27) . Propafenone is a unique antiar-
rhythmic drug and its efficacy in patients with ventricular
arrhythmias has been confirmed clinically (28) .
Antiarrhythmic action and cardioprotective effect. Regard-
less of the subclassification of class I antiarrhythmic drugs,
every drug used here showed a cardioprotective effect as
well as an antiarrhythmic effect . It is well known that
intraaortic balloon pumping suppresses ventricular arrhyth-
mias associated with severe ischemia, and these favorable
effects might be ascribed to the improvement in the hemo-
dynamic state (2 ) . It is also reported that the severity of
ventricular arrhythmias observed in ischemia depends on the
extent of necrosis (30) . Accordingly, the cardioprotective
effect of class I antiarrhythmic drugs observed here might
Nonischemic area
Ischemic area
114 .6
 3 .2
± 2  .8
± 34 .0
1  . 
13 .8
± 5 .1
± 6 .6
22 .4
13 .8
± 3 .6
± 5 .4*
21 .5
10 .6
± 3 .6
± 2 .0*
23 .3 -±2 .7
11 .7 ± 3 .2*
 1 .1 ± 16 . 
117 .3 ± 14 .7*
B
. Total Activity of N-Acetyl-/3-Glucosaminidase (nmol/g wet weight per min) in Myocardial Fraction in the Ischemic Area in All Groups
Control  3 .2 ± 34 .0 13 .8 ± 6 .6
13 .8 ± 5 .4 10 .6 ± 2 .0 11 .7 ± 3 .2 117 .3 ± 14 .7
Aprindine 123 .7 ± 25 .  15 .  ± 7 .0 21 .3 ± 5 .5+ 17 .8
± 6 .0* 18.6±5 .1*  3 .4 ± 7 .2*
Disopyramide
10  .3 ± 36 .1 18 .8 ± 2 .5 23 .0 ± 3 .5* 1  .3 ± 3 .5* 21 .8±5 .1*
 0. ±23 .8*
Flecainide 103 .8 ± 18 .5 18 .4 ± 3
.3 20 .5 ± 2 .7+ 20.1 ± 3 .0* 20. ±3 .7*
88 .2 ± 13 .5*
Lidocaine 111 .  ± 23 .0 17 .6 ± 1 .  20 .5 ± 3 .5+
18 .4 ± 3 .4* 20 .  ± 3 .8+ 87 .0 ± 5 .4t
Mexiletine
116
.4 ± 27
.7 15 .6 ± 5 .3 22 .0 ± 5 .1* 1  .4 ± 5 .3* 18.0±5 .3+
 0 .6 ± 12 .4*
Pentisomide 117 .  ± 17 .3 18 .4 ± 1 .4
22 .4 ± 5 .0* 17 .3 ± 3 .1+ 21 .4 ± 3 .1* 8  .2 ± 11 .7*
Propafenone
100 .6 ± 10 .6 18 .3 ± 0 .8 22 .6 ± 7 .8* 21 .2
± 3
.0*
21 .0 ± 1 .2*  3 .4 ± 13 .1*
C . Total Activities of /3-Glucuronidase (µg/g wet weight per h) in Myocardial Fraction in the Control Group
Nonischemic area 83 .  ± 28 .  15 .1 ± 5 .3
20 .0 ± 3 .2 20 .3 ± 2 .  23 .0 ± 3 .3 71 .3 ± 17 .2
Ischemic area 76 .1 ± 14 .1 8 .1 ± 4 .8+ 12 .4 ± 2 .8*
10 .2
± 2 .0*
10. ±3 .3* 108 .  ± 15 .5*
D. Total Activity of /3-Glucuronidase (µg/g wet weight per h) in Myocardial Fraction in the Ischemic Area in All Groups
Control 76 .1 ± 14 .1 8 .1 ± 4 .8 12 .4
± 2 .8 10 .2 ± 2 .0 10 .  ± 3 .3 108 .  ± 15 .5
Aprindine 87 .5 ± 21 .0 14 .  ± 1 . .' 1  .  ± 3 . * 17 .3 ± 3 . t
17 .6 ± 2 .7+ 77 .7 ± 1  .2*
Disopyramide
85 .7 ± 14 .7 14 .4 ± 3 .7T 18 .5
± 2 .8+
1  .7 ± 2 .5* 18.4±3 .1*
81 .6 ± 17 .6*
Flecainide 8  .2 ± 34 .  17 .2 ± 3 .7* 18 .5
± 3
.5+
18 .1 ± 2 .6* 18.7±4 .4* 7  .2 ± 17 . *
Lidocaine 74 .6 ± 21 .5 16 .1 ± 4 .1* 18 .2 ± 2 .3+ 16 .8 ± 4 .6+ 20.5±3
.0* 73 .2 ± 6 .4*
Mexiletine 85
.6
± 2 
.1 13 .0 ± 4 .1 17 .  ± 2 .3+ 17 .5 ± 5 .2* 18.0±4 .1* 81 .7±11 .5*
Pentisomide 85 .8 ± 1  .2 14 .6 ± 4 .6k 21.8 ± 6 .5*
16 .8 ± 2 .4* 20.4±5 .4* 77.2±6 .2*
Propafenone 86 .4 ± 12 .3 13 .8 ± 6 .3 1  .7 ± 3 .0* 20 .7 ± 4 .3* 21 .7±3 . *
80 .6 ± 12 .0*
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contribute to their antiarrhythmic effect . The major action of
class I antiarrhythmic drugs is based on the inhibition of the
sodium channel (31) . Jennings et al . (32) reported that
sodium and water content increased in ischemic myocar-
dium. From our results, sodium influx might play an impor-
tant role in the development of ischemia-induced myocardial
damage . It is well known that the calcium ion plays an
important role in both the genesis of myocardial injury and
the development of arrhythmias . It could not be ruled out
that class I antiarrhythmic drugs might alter the regulation of
intracellular calcium ion such as the release of calcium ion
from sarcoplasmic reticulum, although further investigation
is necessary to clarify the details .
We should emphasize that every class I drug used here,
although differing in subgroup classification, protects myo-
cardium against ischemia, and that administration of class I
drugs might favorably alter metabolic changes in patients
with acute ischemia because the doses used in the present
study are similar to those used clinically .
We express our appreciation to Michael Bodman . a language consultant of our
department, for reading the previous draft and making suggestions on lan-
guage and style .
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